[Tendencies of prescriptions for neuralgic pain in National Suruga Sanatorium (leprosy), Japan during last 11 years].
The number of ex-leprosy patients has reduced rapidly who were forced to be admitted under leprosy prevention/segregation law and are staying at national sanatoriums with different disabilities due to different physical and social reasons for long time in Japan. Most of them have been of clinically cured status for decades after effective chemotherapy. Some have still been suffering from acute or chronic neuralgic pains which are supposed to be long standing consequences of nerve damage of leprosy and getting medications for long period. Pharmacy department of National Suruga Sanatorium has studied the amount of prescriptions of some medicines for last 11 years, which were thought to be prescribed for pain including neuralgic pain. There seem to be some tendencies of medications during last decade. VitaminB12 (Mecobalamine) is one of the commonest drugs for neuralgic pain at this sanatorium and the amount of prescription had almost been unchanged through the years. Prescription of non-steroid anti-inflammatory drugs (NSAIDs) increased year by year, which may reflect the increasing age of ex-patients who need more pain killers for their painful joints or back. Loxoprofen is the most popular pain killer here and increased by ten times for last decade. The number of prescription for Pentazocine and Hydroxyzine Hydrochloride injection increased for last several years, which reflects a few patients who were still suffering from severe chronic neuralgia for years. It is desirable that a standard regimen for chronic neuralgic pain as a consequence of nerve impairment in leprosy will be developed as soon as possible.
Yamada
Akatsuki
A
National Suruga Sanatorium, Gotemba-city, Shizuoka, Japan. akatsuki@suruga.hosp.go.jp
Horita
Munekatsu
M
Shindo
Kazuaki
K
Ishida
Yutaka
Y
Maeda
Mitsuyoshi
M
D000368:Aged; D000700:Analgesics / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002908:Chronic Disease; D004363:Drug Utilization / Q000706:statistics & numerical data* / Q000639:trends*; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007914:Leper Colonies / Q000706:statistics & numerical data*; D007917:Leprostatic Agents / Q000008:administration & dosage; D007918:Leprosy / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology*; D010423:Pentazocine / Q000008:administration & dosage; D010666:Phenylpropionates / Q000008:administration & dosage; D055656:Prescriptions / Q000706:statistics & numerical data*; D013995:Time; D014805:Vitamin B 12 / Q000008:administration & dosage
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D007917:Leprostatic Agents; D010666:Phenylpropionates; C040656:loxoprofen; D014805:Vitamin B 12; D010423:Pentazocine